Drug intelligence / Profile preview

ICTCAR 023

Development stage: Unknown
Lead developer: Henan Provincial People's Hospital
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

**ICTCAR 023** is an investigational engineered CAR-T cell therapy developed by Innovative Cellular Therapeutics for relapsed/refractory thyroid cancer. The product is described as targeting thyroid-stimulating hormone receptor and CD19, enabling engineered T cells to recognize antigen-positive cells and mediate cytotoxic antitumor activity. The exact product name dPD-1(TSHR+CD19) CAR-T was registered in China in phase 1 studies for relapsed/refractory thyroid cancer. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=38207))

Other names: dPD-1 (TSHR+CD19) CAR-TdPD-1 (TSHR+CD19) CART cellsdPD-1(TSHR+CD19) CAR-T

Targets

CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)TSHR (Thyroid-stimulating hormone receptor)

Beyond the preview

Go deeper on ICTCAR 023.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICTCAR 023.

Explore the full profile